Information Provided By: 
Fly News Breaks for May 3, 2017
ARRY
May 3, 2017 | 06:02 EDT
JPMorgan analyst Anupam Rama upgraded Array BioPharma to Overweight saying current share levels offer a "compelling entry point" ahead of key events starting in the second half of 2017. The analyst now believes the takeover premium has been totally washed out of the stock. Rama lists the Columbus filing in BRAF melanoma by mid-year and initial safety data from the phase 3 Beacon study in colorectal cancer as potential catalysts. He raised his price target for the shares to $10 from $9.
News For ARRY From the Last 2 Days
ARRY
Apr 24, 2024 | 11:02 EDT
Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).
